EGFR and non-small cell lung carcinoma: This meta-analysis was conducted to directly compare the risk of developing all-grades hepatotoxicity associated with new-generation EGFR-TKIs (afatinib, osimertinib and dacomitinib) vs. first-generation EGFR-TKIs (gefitinib and erlotinib) in patients with NSCLC.